GoodRx Holdings, Inc. - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. GoodRx Holdings, Inc. operates a digital healthcare platform in the United States, primarily offering prescription price comparison tools, subscription programs, and pharmaceutical manufacturer solutions. The company operates as a single reporting segment.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $202.97 million | $197.88 million |
| Net Income (Loss) | $11.05 million | ($1.01 million) |
| Operating Income | $23.38 million | $7.38 million |
| Adjusted EBITDA | $69.81 million | $62.79 million |
| Adjusted EBITDA Margin | 34.4% | 31.7% |
| Cash and Cash Equivalents | $300.98 million | $533.30 million (End of Q1 2024) |
| Debt (Principal) | $498.75 million | $500.00 million |
| Monthly Active Consumers | 6.4 million | 6.7 million |
Material Changes vs. Prior Period
- Profitability: The company returned to profitability with a net income of $11.1 million, compared to a net loss of $1.0 million in Q1 2024. Operating income increased significantly to $23.4 million.
- Revenue Growth: Total revenue increased 3% year-over-year. Pharma manufacturer solutions revenue grew 17% to $28.6 million, while Subscription revenue declined 7% to $21.0 million due to the sunset of the Kroger Savings program in July 2024.
- Expense Management: General and administrative expenses decreased 28% ($11.5 million), largely driven by the absence of a $13.0 million legal settlement loss recognized in Q1 2024. Sales and marketing expenses decreased 6%.
- Consumer Metrics: Monthly Active Consumers (MAC) declined 4% to 6.4 million, attributed to changes in the retail pharmacy landscape, including store closures and reimbursement model shifts.
- Acquisition: On January 13, 2025, GoodRx acquired VCRx for $30.0 million in cash to expand its prescription savings platform.
Guidance, Outlook, and Risks
- Outlook: Management expects a near-term year-over-year decline in Monthly Active Consumers due to retail pharmacy reimbursement model changes. However, they anticipate prescription volume will migrate to other in-network pharmacies, making the impact largely transient.
- Legal Contingencies: A $25.0 million settlement regarding a consumer privacy class action was agreed upon in November 2024 and is accrued as a liability, pending court approval in June 2025. The company is also defending against securities class action and derivative lawsuits, for which no loss has been accrued as it is not deemed probable or estimable.
- Market Risks: The filing highlights risks related to the bankruptcy of retail partners (e.g., Rite Aid), which could impact revenue, though Rite Aid is forecasted to represent less than 5% of 2025 revenue. Macroeconomic factors, including inflation and interest rates, remain a concern.
- Capital Allocation: The company repurchased 23.3 million shares of Class A common stock for approximately $100.9 million during the quarter. As of March 31, 2025, $189.4 million remained available under the current repurchase program.
Investor Verification Checklist
- Legal Settlement Finality: Verify the status of the $25.0 million privacy class action settlement and the June 2025 court approval hearing.
- Pharmacy Partner Impact: Monitor the actual revenue impact of Rite Aid's bankruptcy proceedings and store closures on prescription transaction volume.
- Consumer Trends: Track whether Monthly Active Consumers stabilize or continue to decline in Q2 2025 as predicted by management.
- Debt Covenants: Confirm continued compliance with the First Lien Net Leverage Ratio covenant, especially given the recent cash outflows for acquisitions and buybacks.
- Subscription Mix: Assess the long-term revenue impact of the Kroger Savings program sunset and the performance of the remaining "Gold" subscription plans.